Other languages Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
5.42 ^USD	+1.12%		-1.81%	-10.71%

Apr. 18	Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	MT
Apr. 18	Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	Apr. 17
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment	Mar. 25
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	Mar. 25
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01
Sector Update: Health Care	Mar. 01
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Friday as Traders Turn Cautious After Major US Data Releases	Mar. 01
Top Premarket Gainers	Mar. 01
Stock Futures Decrease Pre-Bell as Earnings Season Winds Down; Asia, Europe Fall	Mar. 01
Amneal Pharmaceuticals' Q4 Adjusted Earnings Decline, Revenue Increases; Sets 2024 Guidance; Shares Rise	Mar. 01
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Mar. 01
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 01
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 01
Amneal Pharmaceuticals Licenses Parkinson's Drug to Zambon Biotech in EU	Feb. 27
Amneal Grants Knight Therapeutics Rights to Parkinson's Disease Drug in Canada, Latin America	Jan. 25
Knight Therapeutics Inc. Enters into Exclusive License Agreement with Amneal Pharmaceuticals, Inc. for IPX203	Jan. 25
Amneal Pharmaceuticals Launches Generic Fluorometholone Ophthalmic Suspension	Jan. 10
Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension	Jan. 10
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year Ended December 31, 2023	Jan. 10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Other languages

Filters